Regenxbio Inc. v. Sarepta Therapeutics, Inc.
Headline: Federal Circuit Affirms No Patent Infringement in Gene Therapy Dispute
Case Summary
This case involves a dispute between two biotechnology companies, Regenxbio Inc. and Sarepta Therapeutics, Inc., over patent rights related to gene therapy. Regenxbio sued Sarepta, alleging that Sarepta's gene therapy products infringed on Regenxbio's patents. The core of the dispute centered on whether Sarepta's methods for delivering gene therapy vectors fell under the scope of Regenxbio's patent claims. The lower court initially ruled in favor of Sarepta, finding that Regenxbio's patent claims were not infringed. Regenxbio appealed this decision to the U.S. Court of Appeals for the Federal Circuit (CAFC). The CAFC reviewed the lower court's interpretation of the patent claims and the evidence presented. Ultimately, the CAFC affirmed the lower court's decision, agreeing that Sarepta's products did not infringe on Regenxbio's patent. The court found that Sarepta's methods did not meet all the requirements of Regenxbio's patent claims, specifically regarding the administration of the gene therapy vectors.
AI-generated summary for informational purposes only. Not legal advice. May contain errors. Consult a licensed attorney for legal advice.
Key Holdings
The court established the following key holdings in this case:
- A patent is not infringed if the accused product or method does not meet every limitation of at least one claim of the patent.
- The court affirmed the district court's finding of non-infringement based on the specific language of the patent claims and the accused methods.
Entities and Participants
Parties
- Regenxbio Inc. (company)
- Sarepta Therapeutics, Inc. (company)
- U.S. Court of Appeals for the Federal Circuit (party)
Frequently Asked Questions (4)
Comprehensive Q&A covering every aspect of this court opinion.
Basic Questions (4)
Q: What was the main issue in this case?
The main issue was whether Sarepta Therapeutics' gene therapy products infringed on patents held by Regenxbio Inc.
Q: What was the lower court's decision?
The lower court ruled that Sarepta's products did not infringe on Regenxbio's patents.
Q: What was the appellate court's decision?
The U.S. Court of Appeals for the Federal Circuit affirmed the lower court's decision, finding no patent infringement.
Q: What is the key legal principle applied in this case?
The key principle is that patent infringement occurs only if the accused product or method meets all the limitations of a patent claim.
Case Details
| Case Name | Regenxbio Inc. v. Sarepta Therapeutics, Inc. |
| Court | cafc |
| Date Filed | 2026-02-20 |
| Docket Number | 24-1408 |
| Outcome | Defendant Win |
| Impact Score | 65 / 100 |
| Legal Topics | patent-law, patent-infringement, gene-therapy, intellectual-property |
| Jurisdiction | federal |
About This Analysis
This AI-generated analysis of Regenxbio Inc. v. Sarepta Therapeutics, Inc. was produced by CaseLawBrief to help legal professionals, researchers, students, and the general public understand this court opinion in plain English.
CaseLawBrief aggregates court opinions from CourtListener, a project of the Free Law Project, and enriches them with AI-powered analysis. Our goal is to make the law more accessible and understandable to everyone, regardless of their legal background.
AI-generated summary for informational purposes only. Not legal advice. May contain errors. Consult a licensed attorney for legal advice.